ForSight Robotics Raises $125 Million in Series B to Power Ophthalmic Surgery with Robotics

Led by technology visionaries Daniel Glozman, PhD(Founder & CEO), Dr. Joseph Nathan(Founder, President & CMO), Prof. Moshe Shoham(Founder & CSO), Sharon Levita(Chief Financial Officer), Yonatan Ushpizin(VP of R&D), Ilanit Edri(VP of People), Yaron Levinson, PhD(VP of Product), Eli Levin(Director of Programs), Shiran Conforti(Director of QA/RA), and Gideon Bregman(VP of Operations), Israel based robotics company ForSight Robotics has raised $125 million in a Series B round led by Eclipse, with participation from an undisclosed strategic investor, the Adani Group, Reiya Ventures, Dr. Fred Moll, and other existing backers. The round brings the company’s total funding to $195 million, as mentioned in TFN.

The new funding will speed up the development and clinical trials of the ORYOM™ Platform—the first robotic system built specifically for ophthalmic surgery. Initially focused on cataract procedures, the platform aims to enhance precision, improve patient outcomes, and reduce Surgeon fatigue, with first-in-human trials expected later this year.

The ORYOM™ Platform—named after the Hebrew word for “daylight”—combines AI, advanced computer vision, and ultra-precise micromechanics to give surgeons full access to all areas of the eye with unprecedented control. Already tested in hundreds of procedures on animal models, the system will eventually expand beyond cataracts to include retinal and glaucoma surgeries.